Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Intelgenx Technologies Corp IGXT


Primary Symbol: T.IGX

Healthcare
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allows for pharmaceutical products that address unmet medical needs. It provides comprehensive pharmaceuticals services to pharmaceutical partners, including research and development (R&D), analytical method development, clinical monitoring, IP and regulatory services. Its manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. Its product portfolio includes Migraine (Rizatriptan), Erectile Dysfunction (Tadalafil), Schizophrenia (Lozapine), Neurodegenerative, Opioid Dependence (Buprenorphine / Naloxone) and others.


TSX:IGX - Post by User

Intelgenx Technologies Corp > NR - decision on Rizaport by April 2019
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1747)
•••
Comment by Ciaoon Nov 24, 2018 7:54am
289 Views
Post# 29017001

RE:RE:NR - decision on Rizaport by April 2019

RE:RE:NR - decision on Rizaport by April 2019
biggerr wrote: I couldn't sell the damn thing because the bid was 75 cents, why such a big spread between bid and ask?


Not very liquid on tsx at times but very liquid on us exchange under igxt.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities